雅祥生技醫藥股份有限公司 Approved
最後更新時間 2025/07/10 , 09:27 PM
最後更新時間 2025/07/10 , 09:27 PM
負責人
Zhang,Hong-Ren
統一編號
27570215
成立日期
2005/03/16
資本額
NT$1,500,000,000
實收資本額
NT$1,370,000,000
股票代號
6652
電話
02-27185128
地址
6F, No. 135, Sec. 3, Minsheng E. Rd., Songshan Dist., Taipei City, 105, Taiwan
董監事
姓名 職稱 持有股份 代表法人
Zhang,Hong-Ren Chairman 2.34%
Xu,Shi-Chang Director 23.72%
Zhang,Wan-Ya Director 1.46% HONG WEI INVESTMENT CO., LTD.
Huang,Wen-Hong Independent Director 0.00%
Yang,Zong-Ren Independent Director 0.00%
Chen,Ji-Wang Independent Director 0.00%
營業項目
  • Manufacture of Medicinal Biological Products(200300)
  • Wholesale of Pharmaceutical and Medical Goods(457112)
  • Wholesale of Pharmaceutical and Medical Goods(457199)
  • Miscellaneous Scientific Research and Development(723000)
  • 公司歷程
  • Change Capital to 1,500,000,000
    2017/07/19
  • Change Capital to 1,200,000,000
    2015/05/19
  • Change Capital to 800,000,000
    2012/06/05
  • 員工人數
    財務報表
    項目 2024 2023 2022
    Operating income - - -
    Operating cost - - -
    Profit (loss) of initial recognition of biological asset and agricultural products - - -
    Profit (loss) on changes in fair value less costs to sell of biological asset for current period - - -
    Operating gross profit (loss) - - -
    Unrealized profit (loss) on sales of goods - - -
    Realized profit (loss) on sales of goods - - -
    Operating gross profit (loss), net - - -
    Operating expenses 41,104 41,482 76,759
    Other gain (loss), net - - -
    Operating profit (loss) -41,104 -41,482 -76,759
    Non-operating income and expenses 8,189 -7,640 64,470
    Net profit (loss) before tax -32,915 -49,122 -12,289
    Income tax expense (benefits) -2,367 2,491 6,021
    Net profit (loss) of ongoing business for the current period -30,548 -51,613 -18,310
    Profit (loss) of closed units - - -
    Profit (loss) of non-jointly controlled equity before merger - - -
    Net profit (loss) for the current period -30,548 -51,613 -18,310
    Other comprehensive profit (loss), net 0 30,774 6,100
    Comprehensive net profit and loss of non-jointly controlled equity before merger - - -
    Total comprehensive profit and loss for the current period -30,548 -20,839 -12,210
    Net profit (loss) attributable to owners of parent company -30,548 -51,613 -18,310
    Net profit (loss) form equity attributable to former owner of business combination under common control - - -
    Net profit (loss) attributable to non-controlling interests - - -
    Comprehensive profit (loss) attributable to owners of parent company -30,548 -20,839 -12,210
    Comprehensive profit (loss) form equity attributable to former owner of business combination under common control - - -
    Comprehensive profit (loss) attributable to non-controlling interests - - -
    Basic earnings per share (yuan) 0 0 0
    項目 2024 2023 2022
    Net cash inflow (outflow) from operating activities -32,088 -43,031 -52,880
    Net cash inflows (outflows) from investing activities 69,485 113,871 -48,626
    Net cash inflow (outflow) from financing activities -2,437 -2,438 -3,431
    Effect of Exchange Rate Changes on Cash and Cash Equivalents 0 635 1,510
    Increase (decrease) in cash and cash equivalents in the current period 34,960 69,037 -103,427
    Beginning balance of cash and cash equivalents 213,692 144,655 248,082
    Ending balance of cash and cash equivalents 248,652 213,692 144,655
    項目 2024 2023 2022
    Current asset 374,407 404,074 419,457
    Non-current asset 3,507 6,184 21,357
    Total asset 377,914 410,258 440,814
    Current liability 7,480 7,670 15,026
    Non-current liability 0 1,606 3,967
    Total liability 7,480 9,276 18,993
    share capital 1,370,000 1,370,000 1,370,000
    Equity - secruity token - - -
    capital reserve 551,513 551,513 551,513
    retained earning -1,551,079 -1,520,531 -1,492,582
    Other equity 0 0 -7,110
    Treasury stock - - -
    Total equity attributable to owners of parent company 370,434 400,982 421,821
    Equity attributable to former owner of business combination under common control - - -
    Equity attributable to non-controlling interest before business merger under common control - - -
    Non-controlling interests - - -
    Total Equity 370,434 400,982 421,821
    Share capital awaiting retirement (unit: share) 0 0 0
    Issued shares of advance equity (unit: shares) 0 0 0
    Treasury shares of the parent company held by the parent company and its subsidiaries (unit: share) 0 0 0
    Net asset value per share 2 2 3
    動產抵押
    下載完整報告查看完整數據
    案件類別 債務人名稱 債務人統編 契約啟始日期 契約終止日期 抵押權人名稱 抵押權人統編 擔保債權金額
    選舉收入(政治獻金)
    收入名稱 收入金額
    總收入金額
    選舉支出(政治獻金)
    支出名稱 支出金額
    總支出金額
    標案拒往
    機關名稱 生效日期 截止日期
    進出口資料
    下載完整報告查看完整數據
    年份 月份 總進口實績(美金) 總出口實績(美金)
    商標
  • EUSOL (設計字)
  • 復吉安
  • 復江安
  • 復吉行
  • 行吉復
  • FEGENN
  • EUSOL 135
  • ES 135 (haFGF)
  • EUSOL 135 (haFGF)
  • EUSOL 135 (Human Acidic Fibroblast Growth Factor)
  • 專利
    政府標案
    標案名稱 機關名稱 決標日期 決標金額 是否得標
    裁判書查詢
  • Determine legal expenses
    2018
  • Others
    2016, 2017, 2018
  • 勞權違規
    日期 違反法規法條 罰鍰金額
    污染源裁處
    污染類別 裁處時間 裁處機關 裁處金額 違反事實 違反法令 裁處書字號 裁處理由及法令 公司地址
    本頁內所載之資料,所載資料之完整性、即時性和正確性仍應以資料來源單位為準。
    公司一有新動態,我們馬上通知你,追蹤公司讓你不錯過任何更新。